Cerebrospinal fluid proteomic profiling of HIV-1-infected patients with cognitive impairment

Wojciech Rozek, Mary Ricardo-Dukelow, Sondra Holloway, Howard Eliot Gendelman, Valerie Wojna, Loyda M. Melendez, Pawel S Ciborowski

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Advanced HIV-1 infection is commonly associated with progressive immune suppression and the development of cognitive, motor, and behavior disturbances. In its most severe form, it is diagnosed as HIV-1 associated dementia (HAD) and can progress to profound functional disability and death. Despite prodigious efforts to uncover biomarkers of HAD, none can adequately reflect disease onset or progression. Thus, we developed a proteomics platform for HAD biomarker discovery and used it to perform a pilot study on cerebrospinal fluid (CSF) from HIV-1-infected people with or without HAD. A 2-dimensional electrophoresis (2-DE) map of a HAD CSF proteome was focused on differentially expressed proteins. 2-DE difference gel electrophoresis (2-D DIGE) analysis showed >90 differences in protein spots of which 20 proteins were identified. Differential expression of 6 proteins was validated by Western blot tests and included vitamin D binding protein, clusterin, gelsolin, complement C3, procollagen C-endopeptidase enhancer 1, and cystatin C. We posit that these proteins, alone or together, are potential HAD biomarkers.

Original languageEnglish (US)
Pages (from-to)4189-4199
Number of pages11
JournalJournal of proteome research
Volume6
Issue number11
DOIs
StatePublished - Nov 1 2007

Fingerprint

Cerebrospinal fluid
Proteomics
Cerebrospinal Fluid
HIV-1
Dementia
Biomarkers
Electrophoresis
Proteins
Bone Morphogenetic Protein 1
Vitamin D-Binding Protein
Gelsolin
Clusterin
Cystatin C
Complement C3
Proteome
Two-Dimensional Difference Gel Electrophoresis
Gels
Cognitive Dysfunction
HIV Infections
Western Blotting

Keywords

  • 2-dimensional electrophoresis
  • Cerebrospinal fluid
  • Cognitive impairment
  • DIGE
  • HAD
  • HIV
  • Proteomics

ASJC Scopus subject areas

  • Biochemistry
  • Chemistry(all)

Cite this

Cerebrospinal fluid proteomic profiling of HIV-1-infected patients with cognitive impairment. / Rozek, Wojciech; Ricardo-Dukelow, Mary; Holloway, Sondra; Gendelman, Howard Eliot; Wojna, Valerie; Melendez, Loyda M.; Ciborowski, Pawel S.

In: Journal of proteome research, Vol. 6, No. 11, 01.11.2007, p. 4189-4199.

Research output: Contribution to journalArticle

Rozek, Wojciech ; Ricardo-Dukelow, Mary ; Holloway, Sondra ; Gendelman, Howard Eliot ; Wojna, Valerie ; Melendez, Loyda M. ; Ciborowski, Pawel S. / Cerebrospinal fluid proteomic profiling of HIV-1-infected patients with cognitive impairment. In: Journal of proteome research. 2007 ; Vol. 6, No. 11. pp. 4189-4199.
@article{b89474d0b27144ec99a37e6d08ad1728,
title = "Cerebrospinal fluid proteomic profiling of HIV-1-infected patients with cognitive impairment",
abstract = "Advanced HIV-1 infection is commonly associated with progressive immune suppression and the development of cognitive, motor, and behavior disturbances. In its most severe form, it is diagnosed as HIV-1 associated dementia (HAD) and can progress to profound functional disability and death. Despite prodigious efforts to uncover biomarkers of HAD, none can adequately reflect disease onset or progression. Thus, we developed a proteomics platform for HAD biomarker discovery and used it to perform a pilot study on cerebrospinal fluid (CSF) from HIV-1-infected people with or without HAD. A 2-dimensional electrophoresis (2-DE) map of a HAD CSF proteome was focused on differentially expressed proteins. 2-DE difference gel electrophoresis (2-D DIGE) analysis showed >90 differences in protein spots of which 20 proteins were identified. Differential expression of 6 proteins was validated by Western blot tests and included vitamin D binding protein, clusterin, gelsolin, complement C3, procollagen C-endopeptidase enhancer 1, and cystatin C. We posit that these proteins, alone or together, are potential HAD biomarkers.",
keywords = "2-dimensional electrophoresis, Cerebrospinal fluid, Cognitive impairment, DIGE, HAD, HIV, Proteomics",
author = "Wojciech Rozek and Mary Ricardo-Dukelow and Sondra Holloway and Gendelman, {Howard Eliot} and Valerie Wojna and Melendez, {Loyda M.} and Ciborowski, {Pawel S}",
year = "2007",
month = "11",
day = "1",
doi = "10.1021/pr070220c",
language = "English (US)",
volume = "6",
pages = "4189--4199",
journal = "Journal of Proteome Research",
issn = "1535-3893",
publisher = "American Chemical Society",
number = "11",

}

TY - JOUR

T1 - Cerebrospinal fluid proteomic profiling of HIV-1-infected patients with cognitive impairment

AU - Rozek, Wojciech

AU - Ricardo-Dukelow, Mary

AU - Holloway, Sondra

AU - Gendelman, Howard Eliot

AU - Wojna, Valerie

AU - Melendez, Loyda M.

AU - Ciborowski, Pawel S

PY - 2007/11/1

Y1 - 2007/11/1

N2 - Advanced HIV-1 infection is commonly associated with progressive immune suppression and the development of cognitive, motor, and behavior disturbances. In its most severe form, it is diagnosed as HIV-1 associated dementia (HAD) and can progress to profound functional disability and death. Despite prodigious efforts to uncover biomarkers of HAD, none can adequately reflect disease onset or progression. Thus, we developed a proteomics platform for HAD biomarker discovery and used it to perform a pilot study on cerebrospinal fluid (CSF) from HIV-1-infected people with or without HAD. A 2-dimensional electrophoresis (2-DE) map of a HAD CSF proteome was focused on differentially expressed proteins. 2-DE difference gel electrophoresis (2-D DIGE) analysis showed >90 differences in protein spots of which 20 proteins were identified. Differential expression of 6 proteins was validated by Western blot tests and included vitamin D binding protein, clusterin, gelsolin, complement C3, procollagen C-endopeptidase enhancer 1, and cystatin C. We posit that these proteins, alone or together, are potential HAD biomarkers.

AB - Advanced HIV-1 infection is commonly associated with progressive immune suppression and the development of cognitive, motor, and behavior disturbances. In its most severe form, it is diagnosed as HIV-1 associated dementia (HAD) and can progress to profound functional disability and death. Despite prodigious efforts to uncover biomarkers of HAD, none can adequately reflect disease onset or progression. Thus, we developed a proteomics platform for HAD biomarker discovery and used it to perform a pilot study on cerebrospinal fluid (CSF) from HIV-1-infected people with or without HAD. A 2-dimensional electrophoresis (2-DE) map of a HAD CSF proteome was focused on differentially expressed proteins. 2-DE difference gel electrophoresis (2-D DIGE) analysis showed >90 differences in protein spots of which 20 proteins were identified. Differential expression of 6 proteins was validated by Western blot tests and included vitamin D binding protein, clusterin, gelsolin, complement C3, procollagen C-endopeptidase enhancer 1, and cystatin C. We posit that these proteins, alone or together, are potential HAD biomarkers.

KW - 2-dimensional electrophoresis

KW - Cerebrospinal fluid

KW - Cognitive impairment

KW - DIGE

KW - HAD

KW - HIV

KW - Proteomics

UR - http://www.scopus.com/inward/record.url?scp=36349014934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36349014934&partnerID=8YFLogxK

U2 - 10.1021/pr070220c

DO - 10.1021/pr070220c

M3 - Article

C2 - 17929958

AN - SCOPUS:36349014934

VL - 6

SP - 4189

EP - 4199

JO - Journal of Proteome Research

JF - Journal of Proteome Research

SN - 1535-3893

IS - 11

ER -